-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Under the influence of the country's continuous promotion of the medical reform policy, the competition among pharmaceutical companies is constantly intensifying.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have begun to sell assets
.
Recently, a number of companies including Renfu Medicine, Ruizhi Medicine, and Tonghua Dongbao have issued relevant announcements
.
On April 2, Renfu Pharmaceutical announced that it planned to transfer 680,087,537 Tianfeng Securities shares to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
According to the announcement, the transaction was caused by Renfu Medicine focusing on its main business and optimizing the company's business structure and asset-liability structure
.
On March 30, Ruizhi Pharmaceutical Technology Co.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
Regarding the sale of assets, Wisdom Pharma said that by setting out the Quantum Hi-Tech and prebiotic businesses, it will help the company focus on the main business of CXO, while optimizing the company's asset and liability structure
.
It is worth mentioning that on March 9, Ruizhi Pharmaceutical also issued an announcement on the sale of assets, saying that it planned to sell 100% equity of its wholly-owned subsidiary Kaihui Pharmaceutical (Shanghai) Co.
, Ltd.
, and the counterparty of the transaction was Chongqing Boteng.
Pharmaceutical Technology Co.
, Ltd.
, the transaction price is 266 million yuan
.
On March 29, Xinrui Medicine announced that Major Bright Holdings Limited, a wholly-owned subsidiary of the company, plans to sell a 25% stake in the target company SECCO International Medical Group Co.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
On March 18, Tonghua Dongbao announced that it planned to transfer 5.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said is conducive to the return of funds, providing financial support for Tonghua Dongbao to deploy innovative drugs
.
In addition to domestic companies, many multinational companies are also accelerating their "slimming" since the beginning of this year
.
A few days ago, Daiichi Sankyo (China) issued an announcement stating that the company transferred the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company producing the preparations to YaoPharma.
The transfer is expected to be completed in August 2022, and the transfer profit from the share transfer is expected to be included in March 2023
.
In addition, it is reported that Sandoz, a generic drug company owned by Novartis, may also be sold to private equity firms Blackstone Group and Carlyle Group for $25 billion
.
In general, many pharmaceutical companies are currently selling or transferring assets
.
Analysts believe that some of these companies have to sell and transfer "returning blood" due to the impact of performance
.
Others, on the other hand, continue to gather resources and re-deploy them
.
It can be foreseen that in 2022, the competition in the pharmaceutical market will become more and more fierce
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In order to compete for the market and focus on the company's business, many pharmaceutical companies have begun to sell assets
.
Recently, a number of companies including Renfu Medicine, Ruizhi Medicine, and Tonghua Dongbao have issued relevant announcements
.
On April 2, Renfu Pharmaceutical announced that it planned to transfer 680,087,537 Tianfeng Securities shares to Hubei Hongtai Group Co.
, Ltd.
by way of agreement transfer, with a total transfer price of RMB 2,123,913,378.
05
.
According to the announcement, the transaction was caused by Renfu Medicine focusing on its main business and optimizing the company's business structure and asset-liability structure
.
On March 30, Ruizhi Pharmaceutical Technology Co.
, Ltd.
issued an announcement on the sale of 100% equity of Quantum Hi-Tech (Guangdong) Biological Co.
, Ltd.
The transaction price is expected to be US$237 million, equivalent to RMB 1.
5 billion
.
Regarding the sale of assets, Wisdom Pharma said that by setting out the Quantum Hi-Tech and prebiotic businesses, it will help the company focus on the main business of CXO, while optimizing the company's asset and liability structure
.
It is worth mentioning that on March 9, Ruizhi Pharmaceutical also issued an announcement on the sale of assets, saying that it planned to sell 100% equity of its wholly-owned subsidiary Kaihui Pharmaceutical (Shanghai) Co.
, Ltd.
, and the counterparty of the transaction was Chongqing Boteng.
Pharmaceutical Technology Co.
, Ltd.
, the transaction price is 266 million yuan
.
On March 29, Xinrui Medicine announced that Major Bright Holdings Limited, a wholly-owned subsidiary of the company, plans to sell a 25% stake in the target company SECCO International Medical Group Co.
, Ltd.
for RMB 44 million
.
For the sale of this asset, the company said it will focus on the promising Chinese patent medicine market and sales
.
On March 18, Tonghua Dongbao announced that it planned to transfer 5.
04% shares of Tebao Bio to Guangzhou Houbao Investment Partnership (Limited Partnership) by agreement transfer.
The transfer price was 20.
16 yuan per share, and the total transfer price was 413 million yuan.
.
This move, the company said is conducive to the return of funds, providing financial support for Tonghua Dongbao to deploy innovative drugs
.
In addition to domestic companies, many multinational companies are also accelerating their "slimming" since the beginning of this year
.
A few days ago, Daiichi Sankyo (China) issued an announcement stating that the company transferred the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company producing the preparations to YaoPharma.
The transfer is expected to be completed in August 2022, and the transfer profit from the share transfer is expected to be included in March 2023
.
In addition, it is reported that Sandoz, a generic drug company owned by Novartis, may also be sold to private equity firms Blackstone Group and Carlyle Group for $25 billion
.
In general, many pharmaceutical companies are currently selling or transferring assets
.
Analysts believe that some of these companies have to sell and transfer "returning blood" due to the impact of performance
.
Others, on the other hand, continue to gather resources and re-deploy them
.
It can be foreseen that in 2022, the competition in the pharmaceutical market will become more and more fierce
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
